# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B. Riley Securities analyst Mayank Mamtani maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price targe...
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $100 price target.
Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitisHigh dose rezpega...
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.